309 related articles for article (PubMed ID: 33291532)
1. Role of Nucleotide Excision Repair in Cisplatin Resistance.
Duan M; Ulibarri J; Liu KJ; Mao P
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291532
[TBL] [Abstract][Full Text] [Related]
2. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
3. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.
Köberle B; Masters JR; Hartley JA; Wood RD
Curr Biol; 1999 Mar; 9(5):273-6. PubMed ID: 10074455
[TBL] [Abstract][Full Text] [Related]
4. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
7. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract][Full Text] [Related]
8. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
Bowden NA
Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
[TBL] [Abstract][Full Text] [Related]
11. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract][Full Text] [Related]
12. A novel function of emodin: enhancement of the nucleotide excision repair of UV- and cisplatin-induced DNA damage in human cells.
Chang LC; Sheu HM; Huang YS; Tsai TR; Kuo KW
Biochem Pharmacol; 1999 Jul; 58(1):49-57. PubMed ID: 10403518
[TBL] [Abstract][Full Text] [Related]
13. Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.
Stubbert LJ; Smith JM; McKay BC
BMC Cancer; 2010 May; 10():207. PubMed ID: 20470425
[TBL] [Abstract][Full Text] [Related]
14. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
[TBL] [Abstract][Full Text] [Related]
15. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment.
Colton SL; Xu XS; Wang YA; Wang G
J Biol Chem; 2006 Sep; 281(37):27117-25. PubMed ID: 16849332
[TBL] [Abstract][Full Text] [Related]
16. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
Li C; Li T; Huang L; Yang M; Zhu G
Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
[TBL] [Abstract][Full Text] [Related]
17. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
Graf N; Ang WH; Zhu G; Myint M; Lippard SJ
Chembiochem; 2011 May; 12(7):1115-23. PubMed ID: 21452186
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
19. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Ferry KV; Hamilton TC; Johnson SW
Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
[TBL] [Abstract][Full Text] [Related]
20. Enhanced nucleotide excision repair capacity in lung cancer cells by preconditioning with DNA-damaging agents.
Choi JY; Park JM; Yi JM; Leem SH; Kang TH
Oncotarget; 2015 Sep; 6(26):22575-86. PubMed ID: 26317794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]